Back to Search
Start Over
HB-EGF Is a Promising Therapeutic Target for Lung Cancer with Secondary Mutation of EGFR T790M .
- Source :
-
Anticancer research [Anticancer Res] 2017 Jul; Vol. 37 (7), pp. 3825-3831. - Publication Year :
- 2017
-
Abstract
- Advanced lung cancer is one of the most lethal malignancies. Many anticancer agents have been developed for lung cancer with epidermal growth factor receptor (EGFR) mutations, but its prognosis remains extremely poor. The development of molecularly-targeted therapies is required for patients with lung cancer with secondary mutation of the EGFR gene. In this study, in order to assess the validity of heparin-binding EGF-like growth factor (HB-EGF) as a therapeutic target for lung cancer with EGFR mutation, we examined the antitumor effects of a specific inhibitor (cross-reacting material 197; CRM197) on lung cancer cells with EGFR mutation. HB-EGF was the most predominantly expressed EGFR ligand in lung cancer cells with EGFR mutation. CRM197 induced significant cell apoptosis and marked suppression of tumorigenicity in lung cancer cells with single or double mutation of EGFR. These results suggest that HB-EGF is a rational target for the treatment of lung cancer with EGFR mutation.<br /> (Copyright© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Subjects :
- Animals
Antineoplastic Agents pharmacology
Apoptosis drug effects
Bacterial Proteins pharmacology
Cell Line, Tumor
ErbB Receptors antagonists & inhibitors
Female
Gefitinib
Humans
Lung Neoplasms genetics
Lung Neoplasms metabolism
Lung Neoplasms pathology
Mice, Inbred BALB C
Mice, Nude
Molecular Targeted Therapy
Mutation
Protein Kinase Inhibitors pharmacology
Quinazolines pharmacology
Tumor Burden drug effects
Antineoplastic Agents therapeutic use
Bacterial Proteins therapeutic use
ErbB Receptors genetics
Heparin-binding EGF-like Growth Factor
Lung Neoplasms drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1791-7530
- Volume :
- 37
- Issue :
- 7
- Database :
- MEDLINE
- Journal :
- Anticancer research
- Publication Type :
- Academic Journal
- Accession number :
- 28668882
- Full Text :
- https://doi.org/10.21873/anticanres.11761